Lung cancer chemoprevention with retinol palmitate

Preliminary data from a randomized trial on stage la non small-cell lung cancer

U. Pastorino, E. Soresi, M. Clerici, G. Chiesa, P. A. Belloni, M. Ongari, M. Valente, G. Ravasi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

On the basis of epidemiologic and experimental evidence of an anticancer activity of vitamin A, a randomized clinical trial was activated in Milan with the aim of evaluating if retinol palmitate administration (per os, 300 000 I.U. daily) after complete resection of stage la non small-cell lung cancer could reduce the occurrence of cancer relapses (within 3 years) and/or the occurrence of new primary tumors (beyond 3 years). By September 1987, 181 patients had entered the trial: 87 in the treatment arm and 94 in the control arm. After a median follow-up of 14 months, the interim analysis was focused on the evaluation of toxicity, compliance, and early recurrences. Although the large majority of patients were affected by skin and mucous membrane desquamation and dryness during treatment, these symptoms were generally mild and well tolerated, and never induced the patient to stop the treatment. Other side effects like headache, hair loss, itching, or dyspepsia were detected at a much lower frequency. Only in 3 patients the treatment was interrupted, because of signs or symptoms potentially related to vitamin A administration. At the time of the analysis, a total of 42 (23% patients had relapsed; 16 (18% in the treated arm, and 26 (28% in the control arm. The largest difference between treated patients and controls was observed for bone metastases (2 vs. 7) and brain metastases (3 vs. 6), and for squamous histology (6 vs. 11). Only 2 cases of new primary cancer were detected, both in the control arm. These results are promising both in terms of tolerance and efficacy of treatment, but given the short median follow-up they must be very cautiously interpreted. A longer follow-up is necessary to establish whether a significant proportion of early recurrences could be prevented, or only delayed, by vitamin A administration.

Original languageEnglish
Pages (from-to)773-782
Number of pages10
JournalActa Oncologica
Volume27
Issue number6
DOIs
Publication statusPublished - 1988

Fingerprint

Chemoprevention
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Vitamin A
Recurrence
Neoplasm Metastasis
Neoplasms
Dyspepsia
Alopecia
Therapeutics
Pruritus
Compliance
Signs and Symptoms
Headache
retinol palmitate
Histology
Mucous Membrane
Randomized Controlled Trials
Bone and Bones
Skin

Keywords

  • Chemoprevention
  • Lung neoplasms
  • Non small-cell lung cancer
  • Retinol

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Lung cancer chemoprevention with retinol palmitate : Preliminary data from a randomized trial on stage la non small-cell lung cancer. / Pastorino, U.; Soresi, E.; Clerici, M.; Chiesa, G.; Belloni, P. A.; Ongari, M.; Valente, M.; Ravasi, G.

In: Acta Oncologica, Vol. 27, No. 6, 1988, p. 773-782.

Research output: Contribution to journalArticle

Pastorino, U. ; Soresi, E. ; Clerici, M. ; Chiesa, G. ; Belloni, P. A. ; Ongari, M. ; Valente, M. ; Ravasi, G. / Lung cancer chemoprevention with retinol palmitate : Preliminary data from a randomized trial on stage la non small-cell lung cancer. In: Acta Oncologica. 1988 ; Vol. 27, No. 6. pp. 773-782.
@article{f384de35f84b432ab3485d19b64f1dd0,
title = "Lung cancer chemoprevention with retinol palmitate: Preliminary data from a randomized trial on stage la non small-cell lung cancer",
abstract = "On the basis of epidemiologic and experimental evidence of an anticancer activity of vitamin A, a randomized clinical trial was activated in Milan with the aim of evaluating if retinol palmitate administration (per os, 300 000 I.U. daily) after complete resection of stage la non small-cell lung cancer could reduce the occurrence of cancer relapses (within 3 years) and/or the occurrence of new primary tumors (beyond 3 years). By September 1987, 181 patients had entered the trial: 87 in the treatment arm and 94 in the control arm. After a median follow-up of 14 months, the interim analysis was focused on the evaluation of toxicity, compliance, and early recurrences. Although the large majority of patients were affected by skin and mucous membrane desquamation and dryness during treatment, these symptoms were generally mild and well tolerated, and never induced the patient to stop the treatment. Other side effects like headache, hair loss, itching, or dyspepsia were detected at a much lower frequency. Only in 3 patients the treatment was interrupted, because of signs or symptoms potentially related to vitamin A administration. At the time of the analysis, a total of 42 (23{\%} patients had relapsed; 16 (18{\%} in the treated arm, and 26 (28{\%} in the control arm. The largest difference between treated patients and controls was observed for bone metastases (2 vs. 7) and brain metastases (3 vs. 6), and for squamous histology (6 vs. 11). Only 2 cases of new primary cancer were detected, both in the control arm. These results are promising both in terms of tolerance and efficacy of treatment, but given the short median follow-up they must be very cautiously interpreted. A longer follow-up is necessary to establish whether a significant proportion of early recurrences could be prevented, or only delayed, by vitamin A administration.",
keywords = "Chemoprevention, Lung neoplasms, Non small-cell lung cancer, Retinol",
author = "U. Pastorino and E. Soresi and M. Clerici and G. Chiesa and Belloni, {P. A.} and M. Ongari and M. Valente and G. Ravasi",
year = "1988",
doi = "10.3109/02841868809094356",
language = "English",
volume = "27",
pages = "773--782",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Lung cancer chemoprevention with retinol palmitate

T2 - Preliminary data from a randomized trial on stage la non small-cell lung cancer

AU - Pastorino, U.

AU - Soresi, E.

AU - Clerici, M.

AU - Chiesa, G.

AU - Belloni, P. A.

AU - Ongari, M.

AU - Valente, M.

AU - Ravasi, G.

PY - 1988

Y1 - 1988

N2 - On the basis of epidemiologic and experimental evidence of an anticancer activity of vitamin A, a randomized clinical trial was activated in Milan with the aim of evaluating if retinol palmitate administration (per os, 300 000 I.U. daily) after complete resection of stage la non small-cell lung cancer could reduce the occurrence of cancer relapses (within 3 years) and/or the occurrence of new primary tumors (beyond 3 years). By September 1987, 181 patients had entered the trial: 87 in the treatment arm and 94 in the control arm. After a median follow-up of 14 months, the interim analysis was focused on the evaluation of toxicity, compliance, and early recurrences. Although the large majority of patients were affected by skin and mucous membrane desquamation and dryness during treatment, these symptoms were generally mild and well tolerated, and never induced the patient to stop the treatment. Other side effects like headache, hair loss, itching, or dyspepsia were detected at a much lower frequency. Only in 3 patients the treatment was interrupted, because of signs or symptoms potentially related to vitamin A administration. At the time of the analysis, a total of 42 (23% patients had relapsed; 16 (18% in the treated arm, and 26 (28% in the control arm. The largest difference between treated patients and controls was observed for bone metastases (2 vs. 7) and brain metastases (3 vs. 6), and for squamous histology (6 vs. 11). Only 2 cases of new primary cancer were detected, both in the control arm. These results are promising both in terms of tolerance and efficacy of treatment, but given the short median follow-up they must be very cautiously interpreted. A longer follow-up is necessary to establish whether a significant proportion of early recurrences could be prevented, or only delayed, by vitamin A administration.

AB - On the basis of epidemiologic and experimental evidence of an anticancer activity of vitamin A, a randomized clinical trial was activated in Milan with the aim of evaluating if retinol palmitate administration (per os, 300 000 I.U. daily) after complete resection of stage la non small-cell lung cancer could reduce the occurrence of cancer relapses (within 3 years) and/or the occurrence of new primary tumors (beyond 3 years). By September 1987, 181 patients had entered the trial: 87 in the treatment arm and 94 in the control arm. After a median follow-up of 14 months, the interim analysis was focused on the evaluation of toxicity, compliance, and early recurrences. Although the large majority of patients were affected by skin and mucous membrane desquamation and dryness during treatment, these symptoms were generally mild and well tolerated, and never induced the patient to stop the treatment. Other side effects like headache, hair loss, itching, or dyspepsia were detected at a much lower frequency. Only in 3 patients the treatment was interrupted, because of signs or symptoms potentially related to vitamin A administration. At the time of the analysis, a total of 42 (23% patients had relapsed; 16 (18% in the treated arm, and 26 (28% in the control arm. The largest difference between treated patients and controls was observed for bone metastases (2 vs. 7) and brain metastases (3 vs. 6), and for squamous histology (6 vs. 11). Only 2 cases of new primary cancer were detected, both in the control arm. These results are promising both in terms of tolerance and efficacy of treatment, but given the short median follow-up they must be very cautiously interpreted. A longer follow-up is necessary to establish whether a significant proportion of early recurrences could be prevented, or only delayed, by vitamin A administration.

KW - Chemoprevention

KW - Lung neoplasms

KW - Non small-cell lung cancer

KW - Retinol

UR - http://www.scopus.com/inward/record.url?scp=0024199767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024199767&partnerID=8YFLogxK

U2 - 10.3109/02841868809094356

DO - 10.3109/02841868809094356

M3 - Article

VL - 27

SP - 773

EP - 782

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 6

ER -